利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.025 秒)

    6,11-3c-bicyclic 8a-azalide derivatives
    5.
    发明申请
    6,11-3c-bicyclic 8a-azalide derivatives 审中-公开
    6,11-3c-双环8a-氮杂芳烃衍生物

    公开(公告)号：US20090149398A1

    公开(公告)日：2009-06-11

    申请号：US10586415

    申请日：2005-01-19

    申请人： Kenneth F. Bartizal ,  Milton L. Hammond ,  Dennis M. Schmatz ,  Robert R. Wilkening

    发明人： Kenneth F. Bartizal ,  Milton L. Hammond ,  Dennis M. Schmatz ,  Robert R. Wilkening

    IPC分类号： A61K31/7048 ,  C07H17/08 ,  A61P3/04 ,  C07H17/00

    CPC分类号： C07H17/08

    摘要： Compounds of Formula (I), and pharmaceutically acceptable salts, esters, and prodrugs thereof: (I) are disclosed, wherein A, B, D, L, X, Y, Z and R2′, are described herein. The compounds exhibit antibacterial properties. The compounds of Formula (I) can be employed to treat or prevent bacterial infections as compounds per se or in the form of pharmaceutically acceptable salts, esters, or prodrugs. The compounds and their salts, esters, and prodrugs can also be employed as ingredients in pharmaceutical compositions, optionally in combination with other antibacterial agents, for the treatment of bacterial infections. Processes for making the compounds are also disclosed.

    摘要翻译： 公开了式（I）化合物及其药学上可接受的盐，酯和前体药物：（I），其中A，B，D，L，X，Y，Z和R2'在本文中描述。 该化合物表现出抗菌性能。 式（I）的化合物可用于治疗或预防细菌感染作为化合物本身或以药学上可接受的盐，酯或前药的形式。 化合物及其盐，酯和前药也可以用作药物组合物中的成分，任选地与其它抗菌剂组合用于治疗细菌感染。 还公开了制备化合物的方法。

    Antifungal combination therapy
    6.
    发明授权
    Antifungal combination therapy 有权
    抗真菌联合治疗

    公开(公告)号：US6069126A

    公开(公告)日：2000-05-30

    申请号：US242831

    申请日：1999-02-24

    申请人： George K. Abruzzo ,  Kenneth F. Bartizal ,  Amy M. Flattery

    发明人： George K. Abruzzo ,  Kenneth F. Bartizal ,  Amy M. Flattery

    IPC分类号： A61K38/12 ,  A61K38/17 ,  A61K38/00 ,  A61K31/415 ,  A61K31/70

    CPC分类号： A61K38/12 ,  A61K38/1709 ,  A61K38/1751

    摘要： There is described antifungal combination therapy comprising the use of known antifungal agents such as the azoles or polyenes in combination with a pneumocandin derivative antifungal agent. More particularly, the invention relates to antifungal combination therapy comprising the use of azoles such as fluconazole, voriconazole, itraconazole, ketoconazole, miconazole, ER 30346, SCH 56592; polyenes such as amphotericin B, nystatin or liposomal and lipid forms thereof such as Abelcet, AmBisome and Amphocil; purine or pyrimidine nucleotide inhibitors such as flucytosine; or polyoxins such as nikkomycins, in particular nikkomycin Z or other chitin inhibitors, elongation factor inhibitors such as sordarin and analogs thereof, mannan inhibitors such as predamycin, bactericidal/permeability-inducing (BPI) protein products such as XMP.97 or XMP.127 or complex carbohydrate antifungal agents such as CAN-296 in combination with a pneumocandin derivative as described herein.

    摘要翻译： PCT No.PCT / US97 / 15987第 一九九九年二月二十四日 102（e）1999年2月24日PCT 1997年9月9日PCT公布。 公开号WO98 / 10782 1998年3月19日的日期描述了抗真菌联合疗法，其包括使用已知的抗真菌剂如唑类或多烯与肺炎球菌衍生物抗真菌剂的组合。 更具体地说，本发明涉及抗真菌联合疗法，其包括使用唑类如氟康唑，伏立康唑，伊曲康唑，酮康唑，咪康唑，ER 30346，SCH 56592; 多烯，如两性霉素B，制霉菌素或脂质体及其脂质形式，如Abelcet，AmBisome和Amphocil; 嘌呤或嘧啶核苷酸抑制剂如氟胞嘧啶; 或多克霉素，例如尼克霉素，特别是尼科霉素Z或其他几丁质抑制剂，延伸因子抑制剂如斯德林因及其类似物，甘露聚糖抑制剂例如预霉素，杀菌/诱导诱导（BPI）蛋白产物如XMP.97或XMP.127 或复合的碳水化合物抗真菌剂如CAN-296与本文所述的肺炎球菌衍生物组合。

    Antifungal combination therapy
    7.
    再颁专利
    Antifungal combination therapy 有权
    抗真菌联合治疗

    公开(公告)号：USRE38984E1

    公开(公告)日：2006-02-14

    申请号：US10325137

    申请日：1997-09-09

    申请人： George K. Abruzzo ,  Kenneth F. Bartizal ,  Amy M. Flattery Feighner

    发明人： George K. Abruzzo ,  Kenneth F. Bartizal ,  Amy M. Flattery Feighner

    IPC分类号： A61K38/00 ,  A61K31/70 ,  A61K31/45

    CPC分类号： A61K38/12 ,  A61K38/1709 ,  A61K38/1751 ,  A61K31/00 ,  A61K2300/00

    摘要： There is described antifungal combination therapy comprising the use of known antifungal agents such as the azoles or polyenes in combination with a pneumocandin derivative antifungal agent. More particularly, the invention relates to antifungal combination therapy comprising the use of azoles such as fluconazole, voriconazole, itraconazole, ketoconazole, miconazole, ER 30346, SCH 56592; polyenes such as amphotericin B, nystatin or liposomal and lipid forms thereof such as Abelcet, AmBisome and Amphocil; purine or pyrimidine nucleotide inhibitors such as flucytosine; or polyoxins such as nikkomycins, in particular nikkomycin Z or other chitin inhibitors, elongation factor inhibitors such as sordarin and analogs thereof, mannan inhibitors such as predamycin, bactericidal/permeability-inducing (BPI) protein products such as XMP.97 or XMP.127 or complex carbohydrate antifungal agents such as CAN-296 in combination with a pneumocandin derivative as described herein.

    摘要翻译： 描述了抗真菌联合疗法，其包括使用已知的抗真菌剂如唑类或多烯与肺炎球菌衍生物抗真菌剂的组合。 更具体地说，本发明涉及抗真菌联合疗法，其包括使用唑类如氟康唑，伏立康唑，伊曲康唑，酮康唑，咪康唑，ER 30346，SCH 56592; 多烯，如两性霉素B，制霉菌素或脂质体及其脂质形式，如Abelcet，AmBisome和Amphocil; 嘌呤或嘧啶核苷酸抑制剂如氟胞嘧啶; 或多克霉素，例如尼克霉素，特别是尼科霉素Z或其他几丁质抑制剂，延伸因子抑制剂如斯德林因及其类似物，甘露聚糖抑制剂例如预霉素，杀菌/诱导诱导（BPI）蛋白产物如XMP.97或XMP.127 或复合的碳水化合物抗真菌剂如CAN-296与本文所述的肺炎球菌衍生物组合。